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A B S T R A C T
Enrollment of children into pediatric clinical trials remains challenging. More effective strategies to improve
recruitment of children into trials are needed. This study used in-depth qualitative interviews with parents who
were approached to enroll their children in a clinical trial in order to gain an understanding of the barriers to
pediatric clinical trial participation.
Twenty-four parents whose children had been offered the opportunity to participate in a clinical trial were
interviewed: 19 whose children had participated in at least 1 clinical trial and 5 who had declined participation
in any trial. Each study aspect, from the initial explanation of the study to the end of the study, can affect the
willingness of parents to consent to the proposed study and future studies. Establishing trust, appropriate timing,
a transparent discussion of risks and benefits oriented to the layperson, and providing motivation for children to
participate were key factors that impacted parents' decisions.
In order for clinical trial accrual to be successful, parents' priorities and considerations must be a central
focus, beginning with initial trial design. The recommendations from the parents who participated in this study
can be used to support budget allocations that ensure adequate training of study staff and improved staffing on
nights and weekends. Studies of parent responses in outpatient settings and additional inpatient settings will
provide valuable information on the consent process from the child's and parent's perspectives. Further studies
are needed to explore whether implementation of such strategies will result in improved recruitment for pe-
diatric clinical trials.
1. Introduction
Since 1997, multiple federal policies have attempted to stimulate
pediatric drug development through encouragement of pediatric-spe-
cific studies [1–5]. Despite these efforts, relatively few pediatric drug
trials have been performed, and many trials have enrolled< 100 par-
ticipants [6,7]. In general, enrollment of children into clinical trials is
challenging because of the relatively small number of available parti-
cipants, ethical concerns regarding participation of children in trials,
and technical challenges such as blood volume collection limitations
and monitoring required for certain trials. These factors are further
complicated by the challenges of obtaining parental consent for the
child to participate [8–10]. Previous studies have shown that parental
willingness to allow their children to participate in clinical trials is
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variable based on numerous factors, including: recruitment strategies
used [11,12], age of the child [11,13], race [14], socioeconomic status
[15], type of study or the perceived risk [15,16], and health status of
the child [13]. Fewer data exist that describe specific operational tactics
and interventions that have the most impact on parents' perceptions of
clinical trials.
Clinical Trials Transformation Initiative (CTTI) is a public-private
partnership co-founded by Duke University and the U.S. Food and Drug
Administration that seeks to develop and drive adoption of practices
that will increase the quality and efficiency of clinical trials [17]. In
2014, CTTI implemented a multifaceted project to characterize the
scientific and operational challenges in the design and conduct of an-
tibacterial drug clinical trials in children [18]. In this article, we de-
scribe the findings from one of those studies. The objective of this CTTI
study was to use in-depth telephone interviews with parents whose
children had been approached to participate in clinical trials in order to
gain a better understanding of parents' decision-making, with particular
attention to the barriers to enrollment and ways to overcome them
when possible.
2. Methods
2.1. Participants
Participants in this study were parents whose children were offered
an opportunity to participate in a clinical trial, regardless of whether
they had agreed to participate. The initial goal of the study was to re-
cruit only parents approached for antibacterial drug development
(ABDD) pediatric trials. Because only a limited number of parents ex-
posed to ABDD trial recruitment were identified, additional parents
who had been approached for other types of pediatric trials were in-
terviewed as well. Potential parent participants were identified through
two approaches: 1) partnership with patient advocates from the neo-
natal intensive care unit follow-up clinic at Duke University (Durham,
NC, USA), who were approached face-to-face regarding participation;
and 2) participant recruitment through Schlesinger Associates, a health-
care marketing research firm (Atlanta, GA USA). Through its national
database, Schlesinger identified parents with children, aged newborn to
17 years old. Schlesinger then emailed the identified parents to ask if
any had been approached about an opportunity to enroll their children
in clinical trials during the last five years. Those who responded posi-
tively were contacted by the study team and screened for eligibility.
Eligible participants gave verbal consent to participate in the study. The
study was approved by the Duke University Health System Institutional
Review Board (IRB). Schlesinger was paid for its recruitment services,
and parents were given a small honorarium as a token of appreciation
for taking the time to share their experiences and insights.
2.2. Data collection and analysis
In 2015, a series of one-on-one in-depth semi-structured telephone
interviews were completed with parents whose children had been of-
fered an opportunity to participate in a clinical trial. Each interview
lasted from 30 min to an hour and was conducted by a single profes-
sional interviewer using an open-ended topic guide of questions
(Appendix). This methodology was chosen because its open-ended
nature allowed for a rich exploration of the topics under investigation.
The interviewer was an independent social scientist with no prior re-
lationship to the participants. Interviews were audio-recorded in order
to facilitate a systematic analysis.
Interview questions related to the factors most salient to parental
decision-making about whether to enroll their child in a pediatric
clinical trial. The interview focused on how parents were approached
about their child's participation, what information was provided at that
time and why they decided whether or not to enroll their child. Parents
who had enrolled their child in any clinical trial were asked to describe
and critique their child's experience during the trial. Data from the
interviews were analyzed using a standard, systematic, qualitative ap-
proach in order to identify themes that emerged from the interviews, to
assess the strength of those themes, and to identify illustrative verbatim
quotations from participants.
3. Results
3.1. Study population
Participants in the study were parents whose children had been
offered an opportunity to participate in a clinical trial (n = 24), in-
cluding 19 parents whose children participated in at least one clinical
trial and 5 parents who declined an opportunity for their children to
participate in any trial. Five participants were recruited from the Duke
patient advocacy group, and 19 were recruited through the marketing
research firm. Three parents were approached when their children were
inpatients in the neonatal intensive care unit, while 21 parents were
approached in the outpatient setting. The parents interviewed re-
presented a wide geographic mix encompassing 13 states. Their chil-
dren ranged from newborns to 14 years of age at the time of approach
for trial participation and had a variety of conditions and illnesses,
including lung infections, asthma, allergies, chronic pain syndromes,
cystic fibrosis, clotting disorders, epilepsy, attention-deficit/hyper-
activity disorder (ADHD), Hashimoto's thyroiditis, and other auto-
immune diseases (Table 1). There was wide variation in the types of
trials represented, from non-interventional studies (e.g., weighing of
infants' diapers) to more interventional studies (e.g., new medications,
new dosages for already approved medications, new devices or delivery
mechanisms).
3.2. Themes identified from participant interviews
3.2.1. The initial contact: trust, timing and empathy
3.2.1.1. Trust is critical. All of the parents interviewed said they would
strongly prefer to first hear about a clinical trial participation
opportunity from either their child's own pediatrician or from a
doctor or other health-care provider caring for them in the hospital,
rather than being approached by a stranger. Being “cold called” by a
Table 1
Clinical trial participation by indication.
Trial type (indication) Participateda (n) Declined participation
(n)
ADHD 2 1
Allergy 2 –
Antibiotic dosage for premature
infants
1b 1
Asthma 4 1
Bipolar disorder 1 –
Breathing problems 1 –
Childhood obesity – 1
Chronic pain 1 –
Clotting disorder 1 –
Cystic fibrosis 3 –
HPV – 1
Insulin 1c –
Mental illness 2d –
Abbreviations: ADHD, attention deficit/hyperactivity disorder; HPV, human papilloma-
virus.
a A participant was counted in the “Participated” group if his/her child participated in
at least one clinical trial.
b The participant was approached for approximately eight clinical trials (to the best of
the participant's recollection) and participated in one.
c The participant was approached for approximately three clinical trials (to the best of
the participant's recollection) and participated in one. Participation was declined in an-
tibiotic studies.
d The two participants were twins.
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researcher about participating in a clinical trial was off-putting to
many, even if the researcher was knowledgeable and friendly.
“I would have preferred that the researcher contact my doctor to tell
me about the study and that my doctor would contact me and dis-
cuss it. It was somewhat uncomfortable being called by someone
who didn't know our child.”
However, if the child had participated in a previous trial, had only a
minor medical condition, or was subject to trial tasks that were not
perceived as risky, parents were more amenable to discussing clinical
trial participation with a stranger.
3.2.1.2. Timing is everything. A few parents of very premature newborns
with long stays in the neonatal intensive care unit said that they were
approached too soon and too often by multiple researchers asking them
to enroll their child in a wide array of clinical trials (including
antibacterial drug trials). They said that the first few days after the
birth was not a good time to approach traumatized parents whose
infants were fragile and their survival uncertain. They suggested that
waiting longer would be more sensitive and likely be met with greater
acceptance:
“The person who approached me was very kind, but there's no great
time to approach a person about [enrolling our baby in a clinical
trial]. It's kinda like the taxman coming to you — there's no good
time. … My son at this point in time still looked lethargic, and he
was barely two pounds … Once he started gaining weight and filling
in and the bruising started going away — then we thought he was
doing a lot better, and we weren't on such tenterhooks. It's better to
approach a parent when the child is doing somewhat better from a
visual perspective.”
3.2.1.3. Empathy is essential. Parents emphasized the importance of
empathy from the study team in both the outpatient and inpatient
settings. Several parents of premature newborns thought that the
investigators who approached them about clinical trial participation
were primarily focused on filling study slots and not focused enough on
showing empathy for the parents or concern for the infants. In fact,
many of those who first approached the parents didn't even know the
name of the baby. Some parents felt their infants were being viewed
purely as “study subjects in a science lab” or “guinea pigs” rather than
as “fragile human beings.”
“I couldn't stand some of the people who asked us about clinical
trials. I just felt like they really got a little too excited about kids
having problems. … Every day they would come by and say, ‘We
think this is wrong or that is wrong, so we're going to stick her for
this and stick her for that.’ They got a little too excited, and it made
us feel like we were in a science lab — like Frankenstein. We had to
tell them to go away.”
3.2.2. Conveying the right message: benefits, risks, and side effects
3.2.2.1. Discussion of benefits. When receiving information about a
study, parents felt that the most important pieces of information they
wanted to hear were: 1) that their child's safety and well-being would
be of primary importance to those conducting the study; and 2) how
their child would “directly benefit” from participating in a particular
study. Parents said they felt reassured when told that someone from the
study team would be available to them by cell phone 24/7 should any
problem occur. The direct benefits of clinical trial participation most
obvious to parents could be the improved health of their child or
tangible improvements in their quality of life. Other benefits that
motivated some parents to consider enrolling their children in a trial
included:
• State-of of-the-art medical assessments of the child's condition: some
parents were enthusiastic about enrolling their children with cystic
fibrosis in a clinical study because they would receive regular
magnetic resonance imaging (MRI) monitoring of their lung condi-
tion rather than the standard chest x-rays (i.e., more extensive data
with less risk).
• Medications that would otherwise be unaffordable or unavailable: a
parent of a child with cystic fibrosis said that the same medication
provided free in the context of the clinical trial would have cost
$4000 a month outside of the study.
• Post-study access to a study drug that was not Food and Drug
Administration (FDA)-approved for all patients who participated in
the trial, including the placebo group.
On the other hand, if parents were not convinced by the study team
that their children could benefit from being in the study, they reported
being unlikely to consent.
“Some of the consent forms made the drugs seem a little too ex-
perimental. The ones we thought were beneficial to [our baby] in
the moment were the ones we said yes to, as long as there were no
bad side effects, because we couldn't play around with her since she
started out so sick. But otherwise, if we could see immediate bene-
fits, we chose it.”
3.2.2.2. Discussion of risks. The vast majority of participants considered
complete disclosure and full transparency to be essential when the
study team explained potential risks and side effects of a clinical trial
intervention. Almost all of the parents interviewed said they would
want to be made aware of whether the possible risks and side effects
their child could experience as a result of participating in a particular
trial were probable, possible, or extremely rare. Very remote risks that
are very unlikely to happen should be identified as such. Percentages
are helpful, e.g., “The risk of [adverse effect on study drug] is less than
0.2%.” Reminding parents that “everyone knows there is some risk with
every medication” is helpful for putting the potential side-effects into
perspective. They said that this information would not only help them
weigh the risks and benefits when deciding whether to enroll their
child, but also would give them an idea of what to look for and what to
do should side effects arise.
“He used a lot of technical terms about side effects, and I couldn't
even tell you what he said because I didn't understand it. I would tell
him to stop with the medical jargon. They need to talk to me like I'm
a 5 year-old. They need to tell me more about the medication in a
way that I could understand.”
Choice of wording also may play a role in parents' willingness to
participate in a clinical trial. Some respondents suggested that the term
“study” is less off-putting than “clinical trial.” Another parent said that
using the more common name of medications is less intimidating than
using their “chemical” names.
3.2.3. Properties of the trial itself affecting decision to participate
If the risks were minimal or unlikely to occur, parents reported that
they were more likely to allow their child to participate in a clinical
trial, even if the study protocol was disruptive to their daily routine.
This was especially true if they thought their child could derive a direct
health benefit or improvement in quality of life. Parents were also more
comfortable having their child participate if the drug had been ap-
proved by the FDA, even for another condition or age group (e.g.,
adults). Several parents whose children participated in trials to de-
termine dosages for children said that having FDA approval gave them
more confidence in the safety of the medication. In addition, knowing
that the trial consisted of “only one dose” of medication was seen as low
risk. A few parents also seemed to gravitate more toward studies where
their child would get what seemed like a “natural” substance that their
body makes.
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Many of the parents interviewed were mystified by placebo studies.
Some didn't understand why they couldn't know whether their child
was receiving the study drug or placebo as the trial was underway.
Some were upset because they were not given this information, even
after the study ended. In the particular case of children with ADHD,
parents did not want to take their children off a medication that was
working well enough, only to then be put on a placebo.
3.2.4. Motivating the children
Many of the parents interviewed said that they discussed the trial
with their children if they were old enough to communicate their
wishes. Typically, a study team member also talked with the children
and even had them sign a consent form indicating that they knew what
was involved in the study and that they were in agreement about par-
ticipating. The majority of the parents said they would be unlikely to try
to coax their child to participate in a study if the child objected.
According to the parents interviewed, the most common reason for
children to reject participation was the need to go through procedures
that were “scary” or painful like MRIs, injections or blood draws. In
other cases, the required time commitment for traveling to the study
site for evaluations interfered with other activities the children pre-
ferred. Some said that to overcome these barriers, it is important for the
study designers to incorporate “motivators” into the study for the child
to participate.
For young children (ages 3 to 7), friendly people, fun activities, a
kid-friendly environment and other children to play with are important
motivators. Access to toys, games, and videos at the study site en-
courages them to want to go back for future appointments. Repeated
expression of praise and enthusiasm from the study staff for their par-
ticipation is also important. Small tangible rewards (e.g., prizes, toys,
tablet games) are also good. The less “medical” their experience and the
less austere the environment (e.g., brightly colored, video games, toys,
kid-sized furniture), the more likely they are to enjoy their participation
in the study and even enroll in future studies.
Older children often are more reluctant to participate in studies
because they prefer to spend their free time with friends or in sports or
school activities, and the incentives they need are different from
younger children. The most successful incentive is money or money
substitute (gift cards or online credits) that provide them the opportu-
nity to buy things they would like to have. Token compensation is ty-
pically inadequate to keep them involved in the study. According to
parents, the compensation should be commensurate with what the child
is being asked to give up in time or undergo in medical evaluation. An
initial “signing bonus” followed by compensation for each of the sub-
sequent appointments is a more attractive model than the promise of a
payoff at the end.
3.2.5. Impact of clinical trial participation
Parents who had decided not to participate in a clinical trial were
asked about barriers to their participation (Table 2). Parents who had
enrolled their children in clinical trials reported that many of the
children had participated in several clinical trials, often with the same
investigators. If their child's first experience was positive, they were
typically open to participating in subsequent studies exploring different
facets of their condition or illness.
The majority of the parents said that their children's experiences in
clinical trials were very positive. Overall, once their children were ac-
tually enrolled in the study, they found the study personnel and phy-
sicians kid-friendly, caring, and responsive. Most parents noted that
staff members were extremely appreciative of the children's participa-
tion, and often praised the children for the important contribution they
were making. Almost all said that their children liked interacting with
the study staff and, in some cases, other children at the study site, and
that they felt that it was “cool to be a part of a medical study.”
Other aspects of study participation that parents appreciated in-
cluded receiving information about their child and the study results.
Parents who had some experience with previous clinical trials also re-
cognized that being involved in these studies can provide positive
“teachable moments” for their children, such as personal discipline,
finishing what you start, developing planning skills, communicating
effectively with adults, and learning the importance of “giving back or
paying it forward” so others benefit.
4. Discussion
In this study of 24 in-depth interviews with parents who were ap-
proached to enroll their children in a clinical trial, themes that emerged
across a majority of participants were identified. These findings were
discussed at a multi-stakeholder expert meeting focused on pediatric
trials in antibacterial drug development, which contributed to the de-
velopment of recommendations to improve the design, conduct, and
feasibility of pediatric trials for those drugs [19]. We found that each
aspect of the study, from the initial explanation of the study to the end
of the study, can affect the willingness of parents to consent to the
proposed study and future studies as well. The need for trust in the
study team was a consistent theme throughout the parent interviews.
Trust could be established in multiple ways, including using layman's
terminology, appropriate sensitivity training by study staff, and keeping
the child's personal provider informed and involved. Parents stressed
the importance of the initial contact person and almost universally
preferred that their child's own trusted provider present the study.
Contact from a “stranger” was much less preferred, and if this type of
approach was necessary it was important that “strangers” be aware of
details about the child (such as the child's name) and the child's medical
condition. These findings are consistent with previous studies in which
parents have reported valuing the involvement of their pediatrician or
own specialist in deciding whether to participate in clinical trials. In
one study of parents of children with cancer, parents reported that
having the treating pediatric oncologist explain a study allowed the
oncologist to present the most amount of information in the most ap-
propriate manner to allow for understanding [20].
Timing of the initial approach was important as well, and represents
a dilemma for research teams who study critically ill children. For very
premature newborn infants, the parents in this study recommended that
study teams refrain from asking for consent in the immediate period
following birth due to the uncertainty of the child's clinical condition
and the stress of adjustment to birth and illness. Study teams often
choose to approach parents of newborn infants during this initial time
period for two major reasons: 1) this period represents a guaranteed
time of access to the mother, when she is still hospitalized; and 2) some
studies require enrollment very early in the newborn's life.
Engagement and motivation of their child was critical for parental
agreement to clinical trial participation. Financial compensation has
previously been shown to influence willingness of adolescents to assent
to clinical trials [21]. The issue of financial compensation is complex
due to ethical concerns, and there is substantial variation among trials
regarding the type of compensation offered. One study examined 69
IRB-approved protocols and found that 48/69 (70%) offered at least
one form of compensation or reimbursement: 33/69 (48%) for travel/
parking, 22/69 (32%) for inconvenience, 13/69 (19%) for time, and 6/
69 (9%) for food [22]. Given the logistical barriers reported by parents,
it is possible that improved compensation or other motivations may be
necessary to improve pediatric trial recruitment in the future [23–25].
Parents who did not consent for their children to participate in
clinical trials reported barriers that are consistent with those reported
in prior studies. In addition to issues regarding the study risks/benefits
and aspects of discussion with the study team, parents cited logistical
issues that prevented them from consenting for their child to participate
in clinical trials, suggesting that flexible scheduling, including evenings
and weekends, are a plus for parents considering enrolling their child in
a trial. In an Australian study of recruitment for an obesity trial, ap-
proximately 80% of non-consenting parents gave time as a reason for
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not participating [26]. Family commitments and transportation pro-
blems were also major concerns in this study. Similar results were also
found among parents of infants with sickle cell anemia who were ap-
proached for a clinical trial of hydroxyurea [27]. Among parents who
did not verbally agree to have their children participate in the study,
the most common reason cited was “too many lab visits/lab draws” and
specifically “transportation problems.” These findings highlight the
importance of logistical considerations when planning pediatric clinical
trials, particularly outpatient trials. Moving forward, as new pediatric
trials are designed for antibacterial drugs, it will be important to con-
sider the suggestions of the participants in this study by budgeting for
time and staff for patient visits on nights and weekends.
The present study was strengthened by the quality of the in-depth
one-on-one interviews, which allowed for deep exploration of complex
issues. Parents also were given the opportunity to provide suggestions
to overcome common barriers to participation. It is, however, im-
portant to acknowledge limitations to this study. Originally, it was in-
tended to explore pediatric antibacterial trials specifically, but given
the small pool of participants, it was not possible to limit the sample to
parents who had been approached for their children's participation in
antibacterial trials. However, the themes generated by this study re-
garding the factors important to successful pediatric trial accrual can be
widely applied to other types of clinical trials. Data were not pro-
spectively collected and represented different research settings, and it
should be noted that the factors involved in participation by parents
and children in clinical trials vary between a clinic-based study with a
relatively low risk intervention and time for consideration, and an in-
tensive-care unit-based study with relatively higher risk interventions,
higher levels of psychological stress, and shorter times available be-
tween presentation of the study and the need for consent. Finally,
participant sociodemographic data were not collected. In previous
studies, sociodemographic factors were associated with willingness to
consent for clinical research and attitudes regarding clinical research
[15,28,29].
5. Conclusions
Parents have ultimate decision-making responsibility for their
children's participation in clinical trials for antibacterial drugs and
other drugs. In order for clinical trials to be successful in enrolling
children, parents' priorities and considerations must be a central focus,
beginning with initial trial design. The recommendations from the
parents in this study can be used to justify budget allocations that en-
sure adequate training of study staff including sensitivity/empathy
training, improved staffing on nights and weekends, and appropriate
compensation for adolescent participants. Further studies are needed to
explore whether implementation of such strategies will result in im-
proved recruitment for pediatric clinical trials.
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Santiago (FDA), Kimberly Bergman (FDA), and Raafat Bishai
(AstraZeneca). The Peds ABDD team designed the evidence gathering
instruments, participated in the data analysis, and synthesized the re-
sults. Rochelle Mills, PhD provided medical writing and editing support.
Appendix
Questions used in qualitative interviews:
I. Introduction
A. Could you begin by telling me a little about yourself and your
family?
B. Can you tell me about any recent serious illnesses or hospitali-
zations that your child/ward has had? What was that like?
II. Questions about experiences and decision-making about taking part
in the pediatric clinical trial
A. Can you tell me a little about how you were approached about
the possibility of enrolling the child in the trial? What was that
process like? (open-ended)
B. Who approached you about the trial? What did that person tell
you about the trial?
C. Were you given a consent form to read and sign? Tell me about
that. What was the consent form like? What did it say about
possible side-effects or risks? What did the (study coordinator)
say about the possible risks and side-effects of the drug under
investigation?
D. Think back to when you were first approached for consent to
have the child take part in the trial. Think aloud for a moment
and tell me all your thoughts, good, bad and indifferent. What
questions did you have?
E. What did you see as reasons to enroll the child in the clinical
trial?
F. What did you see as reasons not to enroll the child in the clinical
trial?
G. Was there anyone who you looked to guide you through the
decision about whether to participate?
H. What kinds of information did you want to see when you were
presented with the possibility of enrolling the child in a pediatric
clinical trial? What information was helpful? What kinds of in-
formation that you didn't receive would you have wanted to
have?
I. At that time, did you want to hear all of the possible side-effects
or risks, even those which would be extremely rare, or did you
only want to hear the risks and side-effects that would be most
likely to occur?
J. How, if at all, could the process of approaching you about a
clinical trial for the child have been different or better as far as
you are concerned?
III. For those who did choose to enroll the child
A. What was your experience and that of the child like in the
clinical trial?
B. In what ways could your experience and the child's experiences
have been different or better as far as you are concerned?
C. Looking back, how do you feel about having enrolled your/the
child in the trial? (open-ended) Would you make the same de-
cision again? Why or why not?
D. If you were on the committee charged with deciding the best
ways to approach parents about enrolling their children in pe-
diatric clinical trials what kind of approach would you re-
commend?
IV. For those who did not choose to enroll the child
A. Can you walk me through your thinking as you made the deci-
sion not to enroll the child in the pediatric clinical trial?
B. What was the child's (father's/mother's) thinking about partici-
pation in the trial? Were you both on the same page or did you
have different opinions about it?
C. Looking back, how do you feel about the decision not to have the
child participate? Would you make the same decision again?
Why or why not?
D. What, if anything, might have been different that would have led
you to have enrolled the child in the trial?
E. What other suggestions would you make to improve the parent
or caregiver/child experience of the clinical trial itself?
F. What would you advise a friend who is considering having her
child take part in a clinical trial for antibiotics?
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